Lucas Guillo1, Ferdinando D'Amico2,3, Mélanie Serrero1, Karine Angioi4, Damien Loeuille5, Antonio Costanzo2,6, Silvio Danese2,7, Laurent Peyrin-Biroulet3. 1. Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France. 2. Department of Biomedical Sciences, Humanitas University, Milan, Italy. 3. Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. 4. Department of Ophthalmology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France. 5. Ingénierie Moléculaire et Ingénierie Articulaire (IMoPA), UMR-7365 CNRS, University of Lorraine and University Hospital of Nancy, Nancy, France. 6. Dermatology, Humanitas Clinical and Research Center - IRCCS, Milan, Italy. 7. Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, Milan, Italy.
Abstract
BACKGROUND AND AIMS: Extraintestinal manifestations are common in inflammatory bowel disease patients, although there are few data available on their diagnosis, management and follow-up. We systematically reviewed the literature evidence to evaluate tools and investigations used for the diagnosis and for the assessment of the treatment response in inflammatory bowel disease patients with extraintestinal manifestations. METHODS: We searched in PubMed, Embase and Web of Science from January 1999-December 2019 for all interventional and non-interventional studies published in English assessing diagnostic tools and investigations used in inflammatory bowel disease patients with extraintestinal manifestations. RESULTS: Forty-five studies (16 interventional and 29 non-interventional) were included in our systematic review, enrolling 7994 inflammatory bowel disease patients. The diagnostic assessment of extraintestinal manifestations was performed by dedicated specialists in a percentage of cases ranging from 60-100% depending on the specific condition. The clinical examination was the most frequent diagnostic strategy, accounting for 35 studies (77.8%). In patients with primary sclerosing cholangitis or rheumatological symptoms, biochemical and imaging tests were also performed. Anti-TNF agents were the most used biological drugs for the treatment of extraintestinal manifestations (20 studies, 44.4%), and the treatment response varied from 59.1% in axial spondyloarthritis to 88.9% in ocular manifestations. No benefit was detected in primary sclerosing cholangitis patients after treatment with biologics. CONCLUSIONS: In the clinical management of inflammatory bowel disease patients with extraintestinal manifestations the collaboration of dedicated specialists for diagnostic investigations and follow-up is key to ensure the best of care approach. However, international guidelines are needed to homogenise and standardise the assessment of extraintestinal manifestations.
BACKGROUND AND AIMS: Extraintestinal manifestations are common in inflammatory bowel diseasepatients, although there are few data available on their diagnosis, management and follow-up. We systematically reviewed the literature evidence to evaluate tools and investigations used for the diagnosis and for the assessment of the treatment response in inflammatory bowel diseasepatients with extraintestinal manifestations. METHODS: We searched in PubMed, Embase and Web of Science from January 1999-December 2019 for all interventional and non-interventional studies published in English assessing diagnostic tools and investigations used in inflammatory bowel diseasepatients with extraintestinal manifestations. RESULTS: Forty-five studies (16 interventional and 29 non-interventional) were included in our systematic review, enrolling 7994 inflammatory bowel diseasepatients. The diagnostic assessment of extraintestinal manifestations was performed by dedicated specialists in a percentage of cases ranging from 60-100% depending on the specific condition. The clinical examination was the most frequent diagnostic strategy, accounting for 35 studies (77.8%). In patients with primary sclerosing cholangitis or rheumatological symptoms, biochemical and imaging tests were also performed. Anti-TNF agents were the most used biological drugs for the treatment of extraintestinal manifestations (20 studies, 44.4%), and the treatment response varied from 59.1% in axial spondyloarthritis to 88.9% in ocular manifestations. No benefit was detected in primary sclerosing cholangitispatients after treatment with biologics. CONCLUSIONS: In the clinical management of inflammatory bowel diseasepatients with extraintestinal manifestations the collaboration of dedicated specialists for diagnostic investigations and follow-up is key to ensure the best of care approach. However, international guidelines are needed to homogenise and standardise the assessment of extraintestinal manifestations.
Authors: Tullia de Risi-Pugliese; Philippe Seksik; Jean-David Bouaziz; François Chasset; Philippe Moguelet; Jean-Marc Gornet; Anne Bourrier; Aurélien Amiot; Laurent Beaugerie; Camille Francès; Sarah Guégan Journal: J Am Acad Dermatol Date: 2018-07-10 Impact factor: 11.527
Authors: Tobias J Weismüller; Palak J Trivedi; Annika Bergquist; Mohamad Imam; Henrike Lenzen; Cyriel Y Ponsioen; Kristian Holm; Daniel Gotthardt; Martti A Färkkilä; Hanns-Ulrich Marschall; Douglas Thorburn; Rinse K Weersma; Johan Fevery; Tobias Mueller; Olivier Chazouillères; Kornelius Schulze; Konstantinos N Lazaridis; Sven Almer; Stephen P Pereira; Cynthia Levy; Andrew Mason; Sigrid Naess; Christopher L Bowlus; Annarosa Floreani; Emina Halilbasic; Kidist K Yimam; Piotr Milkiewicz; Ulrich Beuers; Dep K Huynh; Albert Pares; Christine N Manser; George N Dalekos; Bertus Eksteen; Pietro Invernizzi; Christoph P Berg; Gabi I Kirchner; Christoph Sarrazin; Vincent Zimmer; Luca Fabris; Felix Braun; Marco Marzioni; Brian D Juran; Karouk Said; Christian Rupp; Kalle Jokelainen; Maria Benito de Valle; Francesca Saffioti; Angela Cheung; Michael Trauner; Christoph Schramm; Roger W Chapman; Tom H Karlsen; Erik Schrumpf; Christian P Strassburg; Michael P Manns; Keith D Lindor; Gideon M Hirschfield; Bettina E Hansen; Kirsten M Boberg Journal: Gastroenterology Date: 2017-03-06 Impact factor: 22.682
Authors: Robert Löfberg; Edouard V Louis; Walter Reinisch; Anne M Robinson; Martina Kron; Anne Camez; Paul F Pollack Journal: Inflamm Bowel Dis Date: 2011-02-23 Impact factor: 5.325
Authors: F Argüelles-Arias; L Castro-Laria; T Lobatón; M Aguas-Peris; M Rojas-Feria; M Barreiro-de Acosta; P Soto-Escribano; M Calvo-Moya; D Ginard-Vicens; M Chaparro-Sánchez; M Hernández-Durán; B Castro-Senosiain; A Fernández-Villaverde; V García-Sánchez; E Domínguez-Muñoz; A Caunedo-Álvarez; J M Herrerías-Gutiérrez Journal: Dig Dis Sci Date: 2013-07-05 Impact factor: 3.199
Authors: M M H Claessen; M W M D Lutgens; H R van Buuren; B Oldenburg; P C F Stokkers; C J van der Woude; D W Hommes; D J de Jong; G Dijkstra; A A van Bodegraven; P D Siersema; F P Vleggaar Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: S Generini; R Giacomelli; R Fedi; A Fulminis; A Pignone; G Frieri; A Del Rosso; A Viscido; B Galletti; M Fazzi; F Tonelli; M Matucci-Cerinic Journal: Ann Rheum Dis Date: 2004-08-05 Impact factor: 19.103
Authors: David T Rubin; Walter Reinisch; Thomas Greuter; Paulo G Kotze; Marcia Pinheiro; Rajiv Mundayat; Eric Maller; Marc Fellmann; Nervin Lawendy; Irene Modesto; Stephan R Vavricka; Gary R Lichtenstein Journal: Therap Adv Gastroenterol Date: 2021-05-16 Impact factor: 4.409